CompletedPhase 4

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

United States17 participantsStarted 2018-08-23

Plain-language summary

This is a double blind placebo controlled trial in Parkinson's disease (PD) patients with neurogenic orthostatic hypotension (NOH). Investigators hypothesize that the study drug (droxidopa) may improve cerebral perfusion more robustly than systemic BP, possibly by direct action within the CNS vasculature. This study is designed to determine if droxidopa improves cerebral perfusion measures in PD patients with NOH, in addition to peripheral BP measures and subjective responses.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Idiopathic Parkinson's disease patients with orthostatic hypotension (Systolic Blood Pressure drop of \> 20 mm hg or Diastolic Blood Pressure drop of \>10 mm hg measured at some point) within a month of inclusion. Exclusion Criteria: * Age \>85 * Concurrent use of Midodrine * Medical conditions that in the opinion of the investigator, might not allow for same completion of the study i.e. unstable angina, neoplasm, etc

What they're measuring

Cerebral perfusion

Timeframe: 8 weeks

Brain oxygenation

Timeframe: 8 weeks

Trial details

NCT IDNCT03229174

SponsorWilliam Ondo, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-02

View on ClinicalTrials.gov More Parkinson Disease trials